March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Quantum Dots As Neuroprotective Factor In A Model Of Retinal Photoreceptor Degeneration
Author Affiliations & Notes
  • Raul Velez-Montoya
    Ophthalmology, University of Colorado Health and Science Center., Aurora, Colorado
    Rocky Mountain Lions Eye Institute, Aurora, Colorado
  • Naresh Mandava
    Ophthalmology, University of Colorado Health and Science Center., Aurora, Colorado
    Rocky Mountain Lions Eye Institute, Aurora, Colorado
  • Conrad R. Stoldt
    Mechanical Engineering, University of Colorado Boulder, Boulder, Colorado
  • Jeffrey L. Olson
    Ophthalmology, University of Colorado Health and Science Center., Aurora, Colorado
    Rocky Mountain Lions Eye Institute, Aurora, Colorado
  • Footnotes
    Commercial Relationships  Raul Velez-Montoya, None; Naresh Mandava, patent application pending for the disclosed device (P); Conrad R. Stoldt, patent application pending for the disclosed device (P); Jeffrey L. Olson, patent application pending for the disclosed device (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6422. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Raul Velez-Montoya, Naresh Mandava, Conrad R. Stoldt, Jeffrey L. Olson; Quantum Dots As Neuroprotective Factor In A Model Of Retinal Photoreceptor Degeneration. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6422.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To study the intravitreal application of pure silicon-based Quantum Dots (QD) and its capabilities to deliver electrical stimulation to the retinal cells and assesses its potential effect on retinal electrophysiology and anatomy.

Methods: : A Royal College of Surgeon (RCS) rat model of retinal degeneration was used in this study. A total of 24 eyes divided in three groups of 8 eyes each; the first group received the silicon-base QD, the second group received a sham injection and the third was used as a control. An Electroretinogram (ERG) was done at baseline and thereafter every week for 9 weeks. At the end of the follow-up, eyes were collected for further pathological analysis and nuclei cell counts.

Results: : Eyes within the QD group showed a definite but transient change in the waves of the ERG, (increasing the amplitude of the b wave) especially in the rod response compared to the sham and control group (p<0.05). The pathological examination demonstrated a higher nuclei count in the QD group, consistent with a higher cell survival rate than in the sham and control group in which cells degenerated as expected.

Conclusions: : Intravitreal injection of silicon-based QD seems to be safe and well tolerated, with no evident toxic reaction and have a beneficial effect by prolonging cell survival rate and improving ERG patterns in a well established model of retinal degeneration.

Keywords: retinal degenerations: hereditary • protective mechanisms • neuroprotection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×